



EXPRESS SCRIPTS®

**Express Scripts, Inc.
Pharmacy and Therapeutics Committee
Proceedings
May 14, 2009**

New Drug Evaluations

The Committee reviewed the following new drugs.

- A. Afinitor™ (everolimus tablets for oral administration) – Novartis**
- B. Coartem® (artemether/lumefrantrine tablets) - Novartis**
- C. Nuvigil™ (armodafinil tablets) – Cephalon, Inc.**
- D. Simponi™ (golimumab injection [subcutaneous]) – Centocor Ortho Biotech**

New Indications for Existing Products

The Committee reviewed the following new indications for existing products: [See product inserts for specific wording.]

- A. PegIntron® (peginterferon alfa-2b injection, powder for solution for subcutaneous use) - Schering Corporation** - Expanded indication to include retreatment of chronic hepatitis C patients who failed to respond or relapsed after treatment with combination alpha interferon/ribavirin therapy.
- B. Humatrope® (somatropin [rDNA origin] injection) - Eli Lilly** – The treatment of growth failure in children born small for gestational age who fail to demonstrate catch up growth by 2 to 4 years of age.
- C. Reclast® (zoledronic acid injection) - Novartis** – For the treatment and prevention of glucocorticoid-induced osteoporosis in patients expected to be on glucocorticoids for at least 12 months.
- D. Lexapro® (escitalopram oxalate tablets/oral solution) - Forest** - The acute and maintenance treatment of major depressive disorder in adolescents 12 to 17 years.
- E. Tygacil® (tigecycline for injection) - Wyeth** - Community-acquired bacterial pneumonia (CAP) caused by *Streptococcus pneumoniae* (penicillin-susceptible isolates), including cases with concurrent bacteremia, *Haemophilus influenzae* (beta-lactamase negative isolates), and *Legionella pneumophila*.
- F. Avastin® (bevacizumab solution for intravenous infusion) Genentech** - Treatment of glioblastoma with progressive disease following prior therapy as a single agent.
- G. Symbyax® (olanzapine and fluoxetine hydrochloride capsule) - Eli Lilly** - New indication: Symbyax is indicated for the acute treatment of treatment resistant depression (major depressive disorder in adult patients, who do not respond to 2 separate trials of different antidepressants of adequate dose and duration in the current episode). Revised indication: Symbyax is indicated for the acute treatment of depressive episodes associated with bipolar I disorder in adult patients. Revision adds the word "acute" to revised indication and clarifies indication for adult patients.
- H. Prozac® (fluoxetine hydrochloride pulvules) AND Zyprexa® (olanzapine tablets)/Zyprexa® Zydis® (olanzapine orally disintegrating tablets) Eli Lilly** - Prozac and olanzapine in combination are indicated for the acute treatment of depressive episodes associated with bipolar I disorder in adult patients. Prozac and olanzapine in combination are indicated for the acute treatment of treatment resistant

depression (major depressive disorder in adult patients, who do not respond to two separate trials of different antidepressants of adequate dose and duration in the current episode).

New Clinical Line Extensions

The Committee reviewed the following new clinical line extensions.

- A. Exforge HCT[®] (amlodipine/valsartan/ hydrochlorothiazide tablets) Novartis
- B. Edluar[™] (zolpidem tartrate sublingual tablets) DJA Global/Orexo
- C. Ryzolt[™] (tramadol hydrochloride extended-release tablets) Purdue Pharma
- D. Ixiaro[®] (Japanese encephalitis vaccine, inactivated, adsorbed suspension for intramuscular injection) Novartis Vaccines
- E. Zolpimist[™] (zolpidem tartrate oral spray) NovaDel Pharma Inc.